News
Podcasts
Events
Jobs
Companies
Hotbeds
More
Advertise

SUBSCRIBE

SUBSCRIBE

News
Podcasts
Events
Jobs
Companies
Hotbeds
More
Advertise

Search Query

Search Results

Looking for jobs? Search jobs

14,578 Results

Type

Article (256)
Company Profile (3)
Press Release (14319)

Section

Business (7736)
Career Advice (3)
Deals (1015)
Drug Development (1505)
Employer Resources (1)
FDA (220)
Job Trends (531)
News (9761)
Policy (409)

Tag

Date

Last 7 days (4)
Last 30 days (27)
Last 365 days (776)
2025 (409)
2024 (911)
2023 (1117)
2022 (3698)
2021 (1389)
2020 (1117)
2019 (928)
2018 (773)
2017 (482)
2016 (354)
2015 (553)
2014 (387)
2013 (214)
2012 (187)
2011 (257)
2010 (267)

Location

Filters

Type

Article (256)
Company Profile (3)
Press Release (14319)

Section

Business (7736)
Career Advice (3)
Deals (1015)
Drug Development (1505)
Employer Resources (1)
FDA (220)
Job Trends (531)
News (9761)
Policy (409)

Tag

Date

Last 7 days (4)
Last 30 days (27)
Last 365 days (776)
2025 (409)
2024 (911)
2023 (1117)
2022 (3698)
2021 (1389)
2020 (1117)
2019 (928)
2018 (773)
2017 (482)
2016 (354)
2015 (553)
2014 (387)
2013 (214)
2012 (187)
2011 (257)
2010 (267)

Location

14,578 Results for "266".

Sort By

Drug Development

Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, announced that the Phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration.

April 15, 2024
·
5 min read
Press Releases

Adult Myopia Market Size to Reach USD 266.6 Million by 2035, Impelled by Technological Advancements in Treatment Options

January 22, 2025
·
7 min read
Drug Development

Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study

Neumora Therapeutics, Inc. today announced the initiation of a Phase 1 single ascending dose / multiple ascending dose study evaluating NMRA-266 in healthy adult participants.

November 27, 2023
·
6 min read
Deals

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Dermata Therapeutics, Inc. today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 516,336 shares of the Company’s common stock, having exercise prices of $9.7665 and $32.

May 17, 2024
·
5 min read
Hyperthermia Cancer Treatment Market Size to Reach US$ 266 Mn by 2030

According to Report Study, the hyperthermia cancer treatment market is predicted to reach US$ 266 Mn by the end of 2030.

August 5, 2022
·
11 min read
Drug Development

FDA Puts Clinical Hold on Neumora’s Schizophrenia Drug Due to Preclinical Safety Signals

Following cases of convulsions in rabbits in a preclinical study, the FDA has placed a clinical hold on Neumora Therapeutics’ Phase I schizophrenia drug candidate NMRA-266.

April 15, 2024
·
2 min read
·
Tristan Manalac
Blood Pressure Monitoring Devices Market Size Worth Around US$ 2.66 Bn by 2027

According to Precedence Research, the global blood pressure monitoring devices market size is expected to be worth around US$ 2.66 billion by 2027 and growing at a CAGR 8.56% from 2022 to 2027.

March 14, 2022
·
5 min read
BioMidwest

Lilly’s tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks

Detailed results from Eli Lilly and Company’s phase 3 SURMOUNT-3 clinical trial evaluating tirzepatide in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes, were published in Nature Medicine and simultaneously presented at ObesityWeek® 2023.

October 15, 2023
·
13 min read
Genetown

Microbot Medical Announces Closing of $2.66 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,209,500 shares of the Company’s common stock (or common stock equivalents) at a purchase price of $2.20 per share of common stock priced at-the-market under Nasdaq rules.

May 24, 2023
·
4 min read
Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen’s (formerly Horizon Therapeutics) DUEXIS®.

March 26, 2024
·
13 min read

1 of 1,458

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Explore
About
More

© 1985 - 2025 BioSpace.com. All rights reserved.

twitter
instagram
facebook
linkedin